Claims for Patent: 10,729,783

Summary for Patent: 10,729,783

Title:	Hollow silica nanoparticles with encapsulated bioactive ingredients, preparation process and applications thereof
Abstract:	The present invention relates to hollow silica nanoparticles as a drug delivery system loading bioactive ingredients. Particularly, the present invention relates to silica nanoparticles comprising multi-layered silica shells with one or more bioactive ingredients encapsulated within and their applications in drug delivery; and processes of preparing the same.
Inventor(s):	Mou; Chung-Yuan (Taipei, TW), Kou; Nai-Yuan (Tainan, TW), Wu; Si-Han (Taichung, TW), Chen; Yi-Ping (Keelung, TW)
Assignee:	NATIONAL TAIWAN UNIVERSITY (Taipei, TW)
Application Number:	15/681,207
Patent Claims:	1. A silica nanoparticle, comprising a plurality of layered silica shells, wherein each shell has meso-pores and encloses a closed hollow space, optionally the innermost hollow closed space has a solid silica core, wherein the space is defined by the distance between any two silica shells or the solid silica core; and one or more bioactive ingredients encapsulated within the space, wherein the bioactive ingredient has a size larger than the pore size of the shell encapsulating it, and wherein the bioactive ingredient in each space may be the same or different. 2. The silica nanoparticle according to claim 1, which has a particle size ranging from about 20 nm to about 500 nm. 3. The silica nanoparticle according to claim 1, which has a particle size ranging from about 20 nm to about 150 nm. 4. The silica nanoparticle according to claim 1, which has two or more shells. 5. The silica nanoparticle according to claim 1, wherein each shell has organosilica residues. 6. The silica nanoparticle according to claim 1, wherein the pore size of the shell is less than 5 nm. 7. The silica nanoparticle according to claim 1, wherein the shells each independently have a thickness of about 2 nm to about 15 nm. 8. The silica nanoparticle according to claim 1, wherein the size of the space is adjustable. 9. The silica nanoparticle according to claim 1, wherein the distance between the shells ranges from 2 nm to 75 nm. 10. The silica nanoparticle according to claim 1, wherein the bioactive ingredient with or without a surface modification can be dispersed in or dissolved in an aqueous phase. 11. The silica nanoparticle according to claim 1, wherein the bioactive ingredient is an enzyme, a protein drug, an antibody, a vaccine, an antibiotic or a nucleotide drug. 12. The silica nanoparticle according to claim 11, wherein the enzyme is agalsidase, imiglucerase, taliglucerase, velaglucerase, alglucerase, sebelipase, laronidase, idursulfase, elosulfase, galsulfase, alglucosidase, asparaginase, glutaminase, arginine deiminase, arginase, methioninase, cysteinase, homocysteinase, phenylalanine hydroxylase, phenylalanine ammonia lyase, urate oxidase, catalase, horseradish peroxidase, superoxide dismutase or glutathione peroxidase. 13. The silica nanoparticle according to claim 1, wherein a poly(ethylene glycol) (PEG) or a tumor targeting ligand is optionally linked to the outer surface of each shell. 14. A method for preparing a silica nanoparticle, comprising the steps of: (a) any one of steps (a-1) and (a-2): (a-1) providing an oil phase, a surfactant, an alkoxysilane and/or silicate source, an aqueous phase optionally containing one or more bioactive ingredients and optionally a co-surfactant to form a water-in-oil (W/O) microemulsion; and (a-2) providing an oil phase, a surfactant, an alkoxysilane and/or silicate source and optionally a co-surfactant to form a mixture; (b) adding an initiating reagent to the W/O microemulsion of (a-1), or adding an aqueous initiating reagent to the mixture of (a-2) to form a W/O microemulsion, and forming a silica nano-core which links the bioactive ingredient on the surface thereof and/or encapsulates the bioactive ingredient therein; (c) providing an aqueous phase containing a bioactive ingredient; (d) introducing an alkoxysilane and/or silicate source to form an additional silica layer enclosing the silica nano-core of (b); (e) optionally repeating the steps (c) and (d) one or more times; (f) performing a destabilizing condition to destabilize the W/O microemulsion and collecting the resulting particle thus formed from the microemulsion; and (g) dispersing the particle collected in step (f) in an aqueous washing phase to obtain the silica nanoparticle; wherein the alkoxysilane and/or silicate source in steps (d) and (e) and optionally that in step (a) comprise at least one organo-alkoxysilane, and wherein the size of the bioactive ingredients is larger than the pore size of the silica shell encapsulating the same. 15. The method according to claim 14, wherein the order of the introduction of the aqueous phase optionally containing one or more bioactive ingredients and the alkoxysilane and/or silicate source in step (a-1) can be reversed or done simultaneously. 16. The method according to claim 14, wherein the oil phase is dodecane, decane, octane, hexane, cyclohexane, benzene, toluene, xylene triglyceride oil or a plant oil. 17. The method according to claim 14, wherein the surfactant is a non-ionic surfactant. 18. The method according to claim 17, wherein the non-ionic surfactant is poly(oxyethylene)nonylphenyl ether, polyoxyethylene glycol sorbitan alkyl ester, polyethylene glycol alkyl ether, glucoside alkyl ether, polyethylene glycol octylphenyl ether, polyethylene glycol alkylphenyl ether, glycerol alkyl ester, polypropylene glycol alkyl ethers, block copolymers, poloxamers, cocamide MEA, cocamide DEA, lauryldimethylamine oxide or polyethoxylated tallow amine. 19. The method according to claim 14, wherein the alkoxysilane and/or silicate sources are each independently the same or different. 20. The method according to claim 14, wherein the alkoxysilane and/or silicate source comprises tetraethoxysilane (TEOS), tetramethoxysilane (TMOS), sodium silicate or a mixture thereof. 21. The method according to claim 14, wherein the organo-alkoxysilane is 2-[methoxy(polyethyleneoxy)propyl]-trimethoxysilane (PEG-trimethoxysilane), 3-aminopropyltrimethoxysilane (APTMS), propyl triethoxy silane, butyl trimethoxy silane, octyl trimethoxy silane, diphenyl diethoxy silane, n-octyl triethoxy silane, mercapto propyl trimethoxy silane, chloro methyl trimethoxy silane, isobutyl triethoxy silane, 3-aminopropyl triethoxysilane, ethyl trimethoxy styrene silane, methyl triethoxysilane, phenyltriethoxysilane (PTEOS), phenyltrimethoxysilane (PTMOS), methyltrimethoxysilane (MTMOS), ethyltriacetoxysilane (ETAS), N-(trimethoxysilylpropyl)ethylenediamine triacetic acid (EDTAS), (3-trihydroxysilyl)propyl methylphosphonate (THPMP), methyltriacetoxysilane (MTAS), N-[3-(trimethoxysilyl)propyl] ethylenediamine, trimethoxysilylpropyl modified (polyethlenimine), (3-mercatopropyl)trimethoxysilane (MPTMS), N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride, zwitterionic silane or a mixture thereof. 22. The method according to claim 14, wherein the alkoxysilane and/or silicate source is a mixture of TEOS and APTMS, a mixture of THPMP, APTMS and TEOS or a mixture of EDTAS, APTMS and TEOS. 23. The method according to claim 14, wherein when step (e) is employed, wherein the number of shells of the silica nanoparticles is determined by the alkoxysilane and/or silicate source, the time of washing and the temperature for conducting the washing. 24. The method according to claim 14, wherein the aqueous phase is water, aqueous buffer, aqueous DMSO solution or aqueous alkanolic solution or co-solvent containing solution. 25. The method according to claim 14, wherein the bioactive ingredients in steps (a), (c) and (e) are each independently the same or different. 26. The method according to claim 14, wherein the bioactive ingredient with or without surface modification can be dispersed or dissolved in an aqueous phase. 27. The method according to claim 14, wherein the bioactive ingredient is an enzyme, a protein drug, an antibody, a vaccine, an antibiotic or a nucleotide drug. 28. The method according to claim 27, wherein the enzyme is agalsidase, imiglucerase, taliglucerase, velaglucerase, alglucerase, sebelipase, laronidase, idursulfase, elosulfase, galsulfase, alglucosidase, asparaginase, glutaminase, arginine deiminase, arginase, methioninase, cysteinase, homocysteinase, phenylalanine hydroxylase, phenylalanine ammonia lyase, urate oxidase, catalase, horseradish peroxidase, superoxide dismutase or glutathione peroxidase. 29. A silica nanoparticle, which is prepared by the method of any of claims 14 to 28.

Details for Patent 10,729,783

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367	May 23, 1994		2037-08-18
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367	September 22, 1999		2037-08-18
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978		2037-08-18
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058	April 30, 2003		2037-08-18
Biomarin Pharmaceutical Inc.	NAGLAZYME	galsulfase	Injection	125117	May 31, 2005		2037-08-18